Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.56 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.56 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 7/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1021696 | 0.89 | ALDH1A1 (0.61) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL12954903 | 0.83 | MAPT (0.60) | LMNASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL12954852 | 0.83 | ACKR3 (0.50) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL1019547 | 0.80 | NPC1 (0.60) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL1018777 | 0.79 | MEN1 (0.57) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| Trifluoroacetic Acid SCHEMBL1023327 | 0.79 | MAPT (0.54) | LMNASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL28052665 | 0.78 | MEN1 (0.53) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL4838001 | 0.78 | CYP2D6 (0.73) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL9645824 | 0.78 | KDM4E (0.94) | LMNASMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL1019998 | 0.78 | KDM4E (0.94) | LMNASMN1; SMN2MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| EP-2190827-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. Organon (NL) | 2010-06-02 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024550-A1 | N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | N.V. ORGANON (NL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | LMNA 1395/4885SMN1; SMN2 4452/4885MEN1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.